

=> fil reg; d stat que 115

FILE 'REGISTRY' ENTERED AT 11:46:34 ON 21 FEB 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 FEB 2003 HIGHEST RN 492991-99-8

DICTIONARY FILE UPDATES: 20 FEB 2003 HIGHEST RN 492991-99-8

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.



Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

L11

STR



*cationic amino acids =*


*Arg  
His*

*Lys  
Pro*

*Trp*

Page 1-A

 = ring or chain nodes & bond



Page 2-A

VAR G1=2-54 4-57/11-54 13-57/19-54 35-57/44-54 46-57/38-54 40-57

*claim 1 w/ limitations  
searched this structure on  
structure on following page*

## NODE ATTRIBUTES:



NSPEC IS RC AT 52  
 NSPEC IS RC AT 53  
 CONNECT IS E2 RC AT 29  
 CONNECT IS E2 RC AT 48  
 CONNECT IS E1 RC AT 50  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

## GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 57


## STEREO ATTRIBUTES: NONE

L12 STR



Page 1-A

 = ring or chain nodes & bond



Page 2-A

VAR G1=2-51 4-54/11-51 13-54/19-51 35-54/44-51 46-54/38-51 40-54

## NODE ATTRIBUTES:

NSPEC IS RC AT 55  
 NSPEC IS RC AT 62  
 CONNECT IS E2 RC AT 29  
 CONNECT IS E2 RC AT 48  
 CONNECT IS E1 RC AT 50  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

## GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 57

STEREO\_ATTRIBUTES: NONE

L15 0 SEA FILE=REGISTRY SSS FUL L11 OR L12

100.0% PROCESSED 10501 ITERATIONS  
SEARCH TIME: 00.00.03

0 ANSWERS

=> fil reg; d stat que 119; fil cap1; d que nos 132; d que nos 135; s 132 or 135  
FILE 'REGISTRY' ENTERED AT 12:00:45 ON 21 FEB 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 20 FEB 2003 HIGHEST RN 492991-99-8  
DICTIONARY FILE UPDATES: 20 FEB 2003 HIGHEST RN 492991-99-8


TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP  
PROPERTIES for more information. See STNote 27, Searching Properties  
in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

L16 STR



REP G1=(3-3) CH2  
NODE ATTRIBUTES:  
DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 23

STEREO ATTRIBUTES: NONE

L18 8938 SEA FILE=REGISTRY SSS FUL L16

L19 805 SEA FILE=REGISTRY ABB=ON L18 AND SQL<6

*sequence length  
less than 6*

FILE 'CAPLUS' ENTERED AT 12:00:45 ON 21 FEB 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Feb 2003 VOL 138 ISS 9  
FILE LAST UPDATED: 20 Feb 2003 (20030220/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

L16 STR  
L18 8938 SEA FILE=REGISTRY SSS FUL L16  
L19 805 SEA FILE=REGISTRY ABB=ON L18 AND SQL<6  
L20 406 SEA FILE=CAPLUS ABB=ON L19 - used text terms to narrow because answer set was too large  
L27 1686 SEA FILE=CAPLUS ABB=ON ALGICIDES/CT  
L28 7286 SEA FILE=CAPLUS ABB=ON ANTIMICROBIAL AGENTS/CT  
L29 67617 SEA FILE=CAPLUS ABB=ON ANTIBACTERIAL AGENTS+OLD/CT  
L30 29799 SEA FILE=CAPLUS ABB=ON ANTIVIRAL AGENTS+OLD/CT  
L31 3057 SEA FILE=CAPLUS ABB=ON PARASITICIDES+OLD/CT  
L32 20 SEA FILE=CAPLUS ABB=ON L20 AND (L27 OR L28 OR L29 OR L30 OR L31)

L16 STR  
L18 8938 SEA FILE=REGISTRY SSS FUL L16  
L19 805 SEA FILE=REGISTRY ABB=ON L18 AND SQL<6  
L20 406 SEA FILE=CAPLUS ABB=ON L19  
L34 31457 SEA FILE=CAPLUS ABB=ON ANTIMICROB?/OBI  
L35 6 SEA FILE=CAPLUS ABB=ON L20(L)L34

L36 21 L32 OR L35

=> d ibib abs hitstr 1-21

L36 ANSWER 1 OF 21 CAPLUS COPYRIGHT 2003 ACS  
ACCESSION NUMBER: 2002:676157 CAPLUS  
DOCUMENT NUMBER: 137:226599  
TITLE: Small peptides capable of modulating the bioadhesion and signal transduction functions of CD66 (CEACAM) family members  
INVENTOR(S): Skubitz, Keith M.; Skubitz, Amy P. N.  
PATENT ASSIGNEE(S): USA  
SOURCE: PCT Int. Appl., 96 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002068601	A2	20020906	WO 2002-US5720	20020227
W: JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				

PRIORITY APPLN. INFO.: US 2001-272113P P 20010228

AB The present invention relates to peptides capable of modulating the function (e.g., signaling or adhesive activities) of CD66 (CEACAM) family members and/or their ligands. Specifically, a series of peptides derived from functional domains of CD66 antigens are used to modulate CD66-mediated cell adhesion or signal transduction.


IT 457857-38-4 457857-39-5 457857-40-8  
457857-41-9 457857-49-7 457857-50-0  
457857-51-1

RL: ARG (Analytical reagent use); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
(amino acid sequence, peptide modulating CD66 function; small peptides capable of modulating bioadhesion and signal transduction functions of CD66 (CEACAM) family members)

RN 457857-38-4 CAPLUS

CN L-Tryptophan, L-isoleucyl-L-seryl-L-isoleucyl-L-arginyl- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 457857-39-5 CAPLUS

CN L-Phenylalanine, L-seryl-L-isoleucyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 457857-40-8 CAPLUS

CN L-Phenylalanine, L-isoleucyl-L-arginyl-L-tryptophyl-L-phenylalanyl- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 457857-41-9 CAPLUS

CN	L-Lysine, L-arginyl-L-tryptophyl-L-phenylalanyl-L-phenylalanyl- (9CI) (CA INDEX NAME)
----	---


Absolute stereochemistry.



RN 457857-49-7 CAPLUS

CN L-Tryptophan, L-seryl-L-isoleucyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 457857-50-0 CAPLUS

CN L-Phenylalanine, L-isoleucyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 457857-51-1 CAPLUS

CN L-Phenylalanine, L-arginyl-L-tryptophyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L36 ANSWER 2 OF 21 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:652625 CAPLUS

DOCUMENT NUMBER: 137:349131

TITLE: Antimicrobial activity of short arginine- and tryptophan-rich peptides

AUTHOR(S): Strom, Morten B.; Rekdal, Oystein; Svendsen, John S.

CORPORATE SOURCE: Department of Chemistry, Faculty of Science, University of Tromso, Tromso, N-9037, Norway

SOURCE: Journal of Peptide Science (2002), 8(8), 431-437

CODEN: JPSIEI; ISSN: 1075-2617

PUBLISHER: John Wiley & Sons Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Highly antimicrobial active arginine- and tryptophan-rich peptides were synthesized ranging in size from 11 to five amino acid residues in order to elucidate the main structural requirement for such short antimicrobial peptides. The amino acid sequences of the peptides were based on previous

studies of longer bovine and murine lactoferricin derivs. Most of the peptides showed strong inhibitory action against the Gram-neg. bacteria *Escherichia coli* and *Pseudomonas aeruginosa*, and the Gram-pos. bacterium *Staphylococcus aureus*. For the most active derivs., the minimal inhibitory concn. values obsd. for the Gram-neg. bacteria were 5  $\mu\text{g/mL}$  (3.5  $\mu\text{M}$ ), whereas it was 2.5  $\mu\text{g/mL}$  (1.5  $\mu\text{M}$ ) for the Gram-pos. bacterium. It was essential for the antimicrobial activity that the peptides contained a min. of three tryptophan and three arginine residues, and carried a free N-terminal amino group and an amidated C-terminal end. Furthermore, a min. sequence size of seven amino acid residues was required for a high antimicrobial activity against *Pseudomonas aeruginosa*. The insertion of addnl. arginine and tryptophan residues into the peptides resulted only in small variations in the antimicrobial activity, whereas replacement of a tryptophan residue with tyrosine in the hepta- and hexapeptides resulted in reduced antimicrobial activity, esp. against the Gram-neg. bacteria. The peptides were non-hemolytic, making them highly potent as prospective antibiotic agents.

IT 359632-13-6P 359632-15-8P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)


(antimicrobial activity of short arginine- and tryptophan-rich peptides)

RN 359632-13-6 CAPLUS


CN L-Tryptophanamide, L-tryptophyl-L-arginyl-L-tryptophyl-L-arginyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 359632-15-8 CAPLUS

CN L-Argininamide, L-arginyl-L-tryptophyl-L-arginyl-L-tryptophyl- (9CI) (CA



use with humans. In general, humans suitable for use with phage display are either brain dead or terminal wean patients. The amt. of phage library (preferably primary library) required for administration must be significantly increased, preferably 5 orders of magnitude to  $10^{14}$  TU or higher, preferably administered i.v. in .apprx.200 mL of Ringer lactate soln. over about a 10-min period. To produce such large phage libraries, the transformed bacterial pellets recovered from up to 500-1000 transformations are amplified up to 10 times in the bacterial host, recovering the phage from each round of amplification and adding LB Tet medium to the bacterial pellet for collection of addnl. phage. Samples of various organs and tissues are collected starting .apprx.15 min after injection of the phage library; samples are processed and phage collected from each organ, tissue or cell type of interest for DNA sequencing to det. the amino acid sequences of targeting peptides. A substantial improvement in the biopanning technique involves polyorgan targeting. It is possible to pool phage collected from multiple organs after a first round of biopanning and inject the pooled sample into a new subject, where each of the multiple organs may be collected for phage rescue, and the protocol repeated for as many rounds of biopanning as desired. In this manner, it is possible to significantly reduce the no. of subjects required for isolation of targeting peptides for multiple organs, while still achieving substantial enrichment of the organ-homing phage. Thus, 320 targeting peptides are identified with specificity for bone marrow, adipose tissue, skeletal muscle, prostate, skin, or multiple organs. The peptides are of use for targeted delivery of therapeutic agents, including gene therapy vectors. Such targeted delivery may be used for detection, diagnosis or treatment of human diseases. In certain embodiments, the peptide may be attached to an imaging agent and administered to a human to obtain an image or to diagnose a disease state. Also disclosed are a large no. of targeting peptide sequences and consensus motifs that are selective for human organs or tissues, obtained by the methods of the present invention.


IT 403703-59-3P

RL: BPN (Biosynthetic preparation); BUU (Biological use, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(targeting peptide for mouse skeletal muscle; phage display libraries and methods for identifying targeting peptides in humans in vivo)

RN 403703-59-3 CAPLUS

CN Glycine, L-leucyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L36 ANSWER 4 OF 21 CAPLUS COPYRIGHT 2003 ACS


ACCESSION NUMBER: 2001:935828 CAPLUS

DOCUMENT NUMBER: 136:64158

TITLE: Modulators of recombination and methods for producing and using the same




PAGE 1-B



RN 383413-39-6 CAPLUS  
CN L-Tyrosine, L-tryptophyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 383413-51-2 CAPLUS  
CN L-Cysteine, L-tryptophyl-L-arginyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 383413-52-3 CAPLUS

CN L-Cysteine, L-tryptophyl-L-arginyl-L-tryptophyl-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 383414-12-8 CAPLUS


CN L-Tryptophanamide, L-tryptophyl-L-tryptophyl-L-cysteinyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 383414-13-9 CAPLUS  
CN L-Tryptophanamide, L-tryptophyl-L-cysteinyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L36 ANSWER 5 OF 21 CAPLUS COPYRIGHT 2003 ACS  
ACCESSION NUMBER: 2001:935662 CAPLUS  
DOCUMENT NUMBER: 136:58855  
TITLE: Chemically-modified peptides, compositions, and methods of production for antimicrobial use  
INVENTOR(S): Kuhner, Carla H.; Romesser, James A.  
PATENT ASSIGNEE(S): Hercules Incorporated, USA  
SOURCE: PCT Int. Appl., 103 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001098362	A2	20011227	WO 2001-US19400	20010615
WO 2001098362	A3	20021205		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001068512	A5	20020102	AU 2001-68512	20010615
PRIORITY APPLN. INFO.:			US 2000-212441P	P 20000616
			WO 2001-US19400	W 20010615

OTHER SOURCE(S): MARPAT 136:58855

AB Compns. and methods for inhibiting and controlling the growth of microbes are disclosed. The compn. comprises at least one chem.-modified peptide with antimicrobial activity and at least one carrier. The method comprises administering an amt., effective for the prevention, inhibition and termination of microbial growth for industrial, pharmaceutical, household and personal care use.


IT 383179-56-4 383179-57-5 383179-58-6  
 383179-59-7 383179-60-0 383179-61-1  
 383179-63-3 383179-64-4 383179-65-5  
 383179-66-6 383179-67-7 383179-68-8  
 383179-69-9 383179-70-2 383179-71-3  
 383179-72-4 383179-73-5 383179-74-6  
 383179-75-7 383179-76-8 383179-77-9  
 383179-78-0

RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (chem.-modified peptides, compns., and methods of prodn. for antimicrobial use)

RN 383179-56-4 CAPLUS

CN L-Arginine, L-arginyl-L-tryptophyl-L-phenylalanyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383179-57-5 CAPLUS

CN L-Phenylalanine, L-arginyl-L-tryptophyl-L-arginyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383179-58-6 CAPLUS

CN L-Arginine, L-arginyl-L-tryptophyl-L-tryptophyl- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 383179-59-7 CAPLUS

CN L-Phenylalanine, L-arginyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383179-60-0 CAPLUS

CN L-Tryptophan, L-arginyl-L-tryptophyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 383179-61-1 CAPLUS


CN L-Tryptophan, L-arginyl-L-phenylalanyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 383179-63-3 CAPLUS  
 CN L-Arginine, L-arginyl-L-tryptophyl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 383179-64-4 CAPLUS  
 CN L-Arginine, L-arginyl-L-tryptophyl-L-tyrosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383179-65-5 CAPLUS

CN L-Arginine, L-arginyl-L-tryptophyl-L-isoleucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383179-66-6 CAPLUS

CN L-Arginine, L-arginyl-L-tryptophyl-L-leucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383179-67-7 CAPLUS

CN L-Arginine, L-arginyl-L-tryptophyl-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383179-68-8 CAPLUS

CN L-Arginine, L-arginyl-L-tryptophyl-L-valyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383179-69-9 CAPLUS

CN L-Arginine, L-arginyl-L-tryptophyl-L-cysteiny- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383179-70-2 CAPLUS

CN L-Arginine, L-arginyl-L-tryptophyl-L-methionyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383179-71-3 CAPLUS

CN L-Arginine, L-arginyl-L-tryptophyl-L-seryl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383179-72-4 CAPLUS


CN L-Arginine, L-arginyl-L-tryptophyl-L-threonyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 383179-73-5 CAPLUS  
CN L-Arginine, L-arginyl-L-tryptophyl-L-asparaginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 383179-74-6 CAPLUS  
CN L-Arginine, L-arginyl-L-tryptophyl-L-glutaminyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383179-75-7 CAPLUS  
CN L-Arginine, L-arginyl-L-tryptophyl-3-(2-naphthalenyl)-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 383179-76-8 CAPLUS

CN L-Arginine, L-arginyl-L-tryptophyl-L-histidyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383179-77-9 CAPLUS

CN L-Arginine, L-arginyl-L-tryptophyl-L-lysyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 383179-78-0 CAPLUS

CN L-Arginine, L-arginyl-L-tryptophylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L36 ANSWER 6 OF 21 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:676632 CAPLUS

DOCUMENT NUMBER: 135:221265

TITLE: Antimicrobial membrane-destabilizing peptidic compounds and formulations

INVENTOR(S): Svendsen, John Sigurd; Haug, Bengt Erik; Marko, Istvan; Rekdal, Oystein; Skar, Merete Linchausen; Stensen, Wenche; Strom, Morten Bohmer

PATENT ASSIGNEE(S): Alpharma AS, Norway; Gardner, Rebecca

SOURCE: PCT Int. Appl., 89 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001066147	A2	20010913	WO 2001-GB1035	20010309
WO 2001066147	A3	20020411		

W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,

MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM,  
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,  
MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1263471 A2 20021211 EP 2001-910034 20010309

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

NO 2002004218      A      20021105      NO 2002-4218      20020904

PRIORITY APPLN. INFO.:

GB 2000-5703 A 20000309

WO 2001-GB1035      W    20010309

AB The invention relates to the use of a mol. comprising a backbone of 2-35 non-H atoms in length, having covalently attached thereto at least two bulky and lipophilic groups and having at least one more cationic than anionic moiety, in the manuf. of a medicament for destabilizing microbial cell membranes, and the use as a membrane-acting antimicrobial agent of a mol. comprising a backbone of 2-35 non-H atoms in length, having covalently attached thereto a super bulky and lipophilic group comprising at least 9 non-H atoms and having at least two more cationic than anionic moieties, and to methods of treatment involving such mols., in particular peptides including peptide derivs., and peptidomimetics.

IT 359632-13-6P 359632-14-7P 359632-15-8P  
359632-16-9P 359632-17-0P 359632-18-1P  
359632-19-2P 359632-39-6P 359632-41-0P  
359632-43-2P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(membrane-stabilizing peptidic compds. for antimicrobials)

RN 359632-13-6 CAPLUS


CN L-Tryptophanamide, L-tryptophyl-L-arginyl-L-tryptophyl-L-arginyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 359632-14-7 CAPLUS


CN	L-Tryptophanamide, L-tryptophyl-L-arginyl-L-tyrosyl-L-arginyl- (9CI)	(CA
	INDEX NAME)	

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 359632-15-8 CAPLUS

CN L-Argininamide, L-arginyl-L-tryptophyl-L-arginyl-L-tryptophyl- (9CI) (CA  
INDEX NAME)


Absolute stereochemistry.



RN 359632-16-9 CAPLUS

CN L-Tyrosinamide, L-tryptophyl-L-arginyl-L-tryptophyl-L-arginyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 359632-17-0 CAPLUS

CN L-Argininamide, L-arginyl-L-tryptophyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 359632-18-1 CAPLUS


CN L-Tryptophanamide, L-tryptophyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 359632-19-2 CAPLUS

CN L-Argininamide, L-tryptophyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 359632-39-6 CAPLUS

CN L-Tryptophan, L-arginyl-L-tryptophyl-L-arginyl-, phenylmethyl ester (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 359632-41-0 CAPLUS


CN D-Tryptophan, L-arginyl-L-tryptophyl-D-arginyl-, phenylmethyl ester (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



RN 359632-43-2 CAPLUS  
CN L-Arginine, L-arginyl-L-tryptophyl-L-tryptophyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 359632-38-5P 359632-40-9P 359632-42-1P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. and reaction; membrane-destabilizing peptidic compds. for antimicrobials)

RN 359632-38-5 CAPLUS  
CN L-Tryptophan, N2-[(1,1-dimethylethoxy)carbonyl]-L-arginyl-L-tryptophyl-L-arginyl-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 359632-40-9 CAPLUS  
CN D-Tryptophan, N2-[(1,1-dimethylethoxy)carbonyl]-L-arginyl-L-tryptophyl-D-arginyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 359632-42-1 CAPLUS

CN L-Arginine, N2-[(1,1-dimethylethoxy)carbonyl]-L-arginyl-L-tryptophyl-L-tryptophyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L36 ANSWER 7 OF 21 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:50820 CAPLUS

DOCUMENT NUMBER: 134:126821

TITLE: Antigenic determinants of antigenic proteins of *Neisseria meningitidis* and their diagnostic, prophylactic and therapeutic use

INVENTOR(S): Masignani, Vega; Scarlato, Vincenzo; Scarselli, Maria; Galeotti, Cesira; Mora, Mariarosa

PATENT ASSIGNEE(S): Chiron S.p.A., Italy

SOURCE: PCT Int. Appl., 80 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----

WO 2001004316 A2 20010118 WO 2000-IB1026 20000713  
WO 2001004316 A3 20010809  
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,  
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,  
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,  
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,  
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
EP 1196587 A2 20020417 EP 2000-944161 20000713  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO  
BR 2000012424 A 20020702 BR 2000-12424 20000713  
JP 2003504062 T2 20030204 JP 2001-509520 20000713  
GB 1999-16529 A 19990714  
WO 2000-IB1026 W 20000713

## PRIORITY APPLN. INFO.:

AB Antigenic determinants of known antigenic proteins of Neisseria meningitidis are characterized. The peptides can be used as diagnostic reagents or as antigens for vaccines and they may be manufd. by expression of a natural or synthetic gene encoding the protein. Homologous sequences and proteins comprising these fragments are also disclosed.


## IT 321868-20-6

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(amino acid sequence, antigenic peptide of Neisseria meningitidis; antigenic determinants of antigenic proteins of Neisseria meningitidis and their diagnostic, prophylactic and therapeutic use)

RN 321868-20-6 CAPLUS

CN L-Asparagine, L-glutaminy-L-arginyl-L-tryptophyl-L-.alpha.-aspartyl-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L36 ANSWER 8 OF 21 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:15029 CAPLUS

DOCUMENT NUMBER: 132:83653


TITLE: Pharmaceutical preparations for use in combatting or preventing surface infections caused by microorganisms  
INVENTOR(S): Swart, Pieter Jacob; Kuipers, Maria Elizabeth; Meijer, Dirk Klaas Fokke; Hageman, Robert Johan Joseph; Van den Berg, Jeroen Johannes Maria

PATENT ASSIGNEE(S): N.V. Nutricia, Neth.  
SOURCE: PCT Int. Appl., 90 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000000214	A2	20000106	WO 1999-EP4067	19990628
WO 2000000214	A3	20000330		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 974360	A2	20000126	EP 1998-203765	19981106
EP 974360	A3	20000329		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AU 9945124	A1	20000117	AU 1999-45124	19990628
EP 1089755	A2	20010411	EP 1999-927966	19990628
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL				
JP 2002519332	T2	20020702	JP 2000-556799	19990628
PRIORITY APPLN. INFO.:				
NL 1998-1009505 A 19980626				
NL 1998-1010284 A 19981009				
EP 1998-203765 A 19981106				
WO 1999-EP4067 W 19990628				
AB	The invention relates to a medicament for treatment and/or prevention of infections caused by bacteria, fungi, viruses and the like, inflammations and/or tumors, said medicament comprising an active amt. of a polycationic peptide or protein, and a buffer for maintaining the pH of treatable tissue within a preselected range.			
IT	145617-76-1 145617-80-7 145617-91-0 146285-68-9 146285-69-0 146285-73-6 146285-74-7 253782-61-5 253782-76-2 253782-77-3 253782-81-9 253782-82-0 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (pharmaceutical preps. for use in combating or preventing surface infections caused by microorganisms)			
RN	145617-76-1 CAPLUS			
CN	L-Arginine, L-arginyl-L-tryptophyl-L-glutaminy-L-tryptophyl- (9CI) (CA INDEX NAME)			

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 145617-80-7 CAPLUS  
CN L-Lysine, L-arginyl-L-tryptophyl-L-glutaminyl-L-.alpha.-glutamyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 145617-91-0 CAPLUS


CN L-Argininamide, L-arginyl-L-tryptophyl-L-glutaminyl-L-tryptophyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 146285-68-9 CAPLUS

CN L-Tryptophan, L-arginyl-L-arginyl-L-tryptophyl-L-glutaminyl- (9CI) (CA  
INDEX NAME)


Absolute stereochemistry.



RN 146285-69-0 CAPLUS

CN L-Glutamine, L-arginyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 146285-73-6 CAPLUS

CN L-Asparagine, L-leucyl-L-arginyl-L-tryptophyl-L-glutaminyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 146285-74-7 CAPLUS

CN L-Glutamine, L-leucyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253782-61-5 CAPLUS

CN L-Lysinamide, L-arginyl-L-tryptophyl-L-glutaminy-L-.alpha.-glutamyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 253782-76-2 CAPLUS

CN L-Tryptophanamide, L-arginyl-L-arginyl-L-tryptophyl-L-glutaminyl- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 253782-77-3 CAPLUS

CN L-Glutamamide, L-arginyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 253782-81-9 CAPLUS

CN L-Aspartamide, L-leucyl-L-arginyl-L-tryptophyl-L-glutaminyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 253782-82-0 CAPLUS

CN L-Glutamamide, L-leucyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L36 ANSWER 9 OF 21 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1997:754271 CAPLUS

DOCUMENT NUMBER: 128:70761

TITLE: Parasitocides containing lactoferrins and anti-infective substances for aquatic animals

INVENTOR(S): Tomita, Mamoru; Hayazawa, Hironori; Kawase, Kyouzo; Yamauchi, Koji; Nakamura, Hirohiko

PATENT ASSIGNEE(S): Morinaga Milk Industry Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 13 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09301807	A2	19971125	JP 1996-114912	19960509
PRIORITY APPLN. INFO.:			JP 1996-114912	19960509
AB Parasitocides for cultured or aquarium fishes contain (A) .gtoreq.1 compds. chosen from lactoferrins, their hydrolyzates, peptides from the				

hydrolyzates, and synthetic peptides having the same amino acid sequence with the peptides and (B) anti-infective substances. A feed contg. 0.005% each of lactoferrin and lactoperoxidase was fed to *Carassius carassius* to control white spot disease.

IT 146285-68-9 146285-69-0 146285-73-6

146285-74-7


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(lactoferrin peptides contg.; parasitocides contg. lactoferrins and anti-infective substances for aquatic animals)

RN 146285-68-9 CAPLUS

CN L-Tryptophan, L-arginyl-L-arginyl-L-tryptophyl-L-glutamyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 146285-69-0 CAPLUS

CN L-Glutamine, L-arginyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 146285-73-6 CAPLUS

CN L-Asparagine, L-leucyl-L-arginyl-L-tryptophyl-L-glutamyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 146285-74-7 CAPLUS

CN L-Glutamine, L-leucyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L36 ANSWER 10 OF 21 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1997:343712 CAPLUS

DOCUMENT NUMBER: 126:316271

TITLE: Structural and immunochemical studies of bovine antimicrobial peptide "lactoferricin"

AUTHOR(S): Shimazaki, Kei-ichi; Soo Nam, Myoung; Harakawa, Shinji; Tanaka, Tetsuyz; Omata, Yoshitaka; Saito, Atsushi; Kumura, Haruto; Mikawa, Katsuhiko; Igarashi, Ikuo; et al.

CORPORATE SOURCE: Dairy Science Laboratory, Animal Science Department, Faculty of Agriculture, Hokkaido University, Sapporo, 060, Japan

SOURCE: Peptide Chemistry (1996), 34th, 197-200

CODEN: PECHDP; ISSN: 0388-3698

PUBLISHER: Protein Research Foundation

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Lactoferrin is a multifunctional protein found in secretory fluids and in blood. Hydrolyzates produced by pepsin cleavage of human or bovine lactoferrin were found to contain a potent bactericidal peptide, named lactoferricin (LFcin). The microbial killing effect of this peptide derived from bovine lactoferrin is stronger than that from human

lactoferrin. The authors examd. the antigenicity of LFcIn B using the monoclonal antibody. By anal. with the synthetic peptides prepd. on cellulose membranes using SPOTSS, and the anal. of the reactivity of the monoclonal antibody against chem. modified derivs. of LFcIn B, the antigenic determinant of LFcIn B was identified to be the sequence of residues "QWR". CD spectra of LFcIn B showed that the peptide consists of mainly .beta.-sheet and unordered structures in aq. soln.

IT 145617-76-1

RL: PRP (Properties)


(structure and immunochem. of bovine antimicrobial peptide lactoferricin)

RN 145617-76-1 CAPLUS


CN L-Arginine, L-arginyl-L-tryptophyl-L-glutaminy-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L36 ANSWER 11 OF 21 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1997:264565 CAPLUS

DOCUMENT NUMBER: 126:234755

TITLE: Parasiticides containing peptides isolated from lactoferrin hydrolyzates

INVENTOR(S): Shimazaki, Keiichi; Saito, Atsushi

PATENT ASSIGNEE(S): Morinaga Milk Industry Co Ltd, Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 11 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09040578	A2	19970210	JP 1995-195218	19950731

PRIORITY APPLN. INFO.: JP 1995-195218 19950731


AB The parasitocides contain a peptide having a sequence of 31 amino acid sequences (sequence given), their pharmaceutically acceptable derivs. or salts, or mixts. of .gtoreq.2 of them as active ingredients. A peptide, i.e. Phe-Lys-Cys\*-Arg-Arg-Trp-Gln-Trp-Arg-Met-Lys-Lys-Leu-Gly-Ala-Pro-Ser-Ile-Thr-Cys\*-Val-Arg-Arg-Ala-Phe (I; 2 Cys\* residues are bonded through a disulfide bond), was isolated from a hydrolyzate obtained by hydrolysis of bovine lactoferrin with porcine pepsin. Infection rate to mouse embryonic cells of Toxoplasma gondii pretreated with I at 1000 .mu.g/mL for 30 min or .gtoreq.1 h was 16 or .ltoreq.10%, resp. Formulations of I, e.g. injections, ointments, were also given.

IT 146285-68-9 146285-69-0 146285-73-6 146285-74-7  
 RL: ADV (Adverse effect, including toxicity); AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (parasitocides contg. peptides isolated from lactoferrin hydrolyzates)

RN 146285-68-9 CAPLUS

CN L-Tryptophan, L-arginyl-L-arginyl-L-tryptophyl-L-glutamyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 146285-69-0 CAPLUS

CN L-Glutamine, L-arginyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 146285-73-6 CAPLUS

CN L-Asparagine, L-leucyl-L-arginyl-L-tryptophyl-L-glutaminyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 146285-74-7 CAPLUS

CN L-Glutamine, L-leucyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



ACCESSION NUMBER: 1996:497256 CAPLUS  
DOCUMENT NUMBER: 125:132783  
TITLE: Lactoferrin-derived peptides as antiulcer drugs  
INVENTOR(S): Shimamura, Seiichi; Takase, Mitsunori; Yamauchi, Koji;  
Wakabayashi, Hiroyuki; Yamazaki, Natsuko  
PATENT ASSIGNEE(S): Morinaga Milk Industry Co Ltd, Japan  
SOURCE: Jpn. Kokai Tokkyo Koho, 11 pp.  
CODEN: JKXXAF  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	JP 08143468	A2	19960604	JP 1994-283869	19941117
PRIORITY APPLN. INFO.:				JP 1994-283869	19941117
AB	Lactoferrin-derived peptides and their salts are claimed as antiulcer drugs. The peptides are water sol., stable in aq. solns., heat-resistant, and orally effective wit min. side effects and have antibacterial effects, thus, no preservatives are needed in their formulations. Thus, tablets contg. the peptides prepd. by autotransfer were formulated, and their antiulcer effects were tested in rats.				
IT	<b>146285-68-9P 146285-69-0P 146285-73-6P</b> <b>146285-74-7P</b>				
	RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (lactoferrin-derived peptides as antiulcer drugs)				
RN	146285-68-9 CAPLUS				
CN	L-Tryptophan, L-arginyl-L-arginyl-L-tryptophyl-L-glutamyl- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



RN 146285-69-0 CAPLUS  
CN L-Glutamine, L-arginyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 146285-73-6 CAPLUS

CN L-Asparagine, L-leucyl-L-arginyl-L-tryptophyl-L-glutaminyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 146285-74-7 CAPLUS

CN L-Glutamine, L-leucyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





ACCESSION NUMBER: 1996:412033 CAPLUS  
DOCUMENT NUMBER: 125:196350  
TITLE: Molecular size of an anti-HIV peptide, T22, can be reduced without loss of the activity  
AUTHOR(S): Waki, Michinori; Waki, Koji; Miyamoto, Kenji; Matsumoto, Akiyoshi; Tamamura, Hirokazu; Fujii, Nobutaka; Murakami, Tsutomu; Nakashima, Hideki; Yamamoto, Naoki  
CORPORATE SOURCE: Seikagaku Corp., Tokyo Res. Inst., Higashiyamato, 207, Japan  
SOURCE: Chemistry Letters (1996), (7), 571-572  
CODEN: CMLTAG; ISSN: 0366-7022  
PUBLISHER: Nippon Kagakkai  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
GI

H-Arg-Arg-Trp-Cys-Tyr-Arg-Lys-X-Tyr-Arg-Lys-Cys-Arg-NH<sub>2</sub> I

Q = -Cys-Tyr-Lys-Gly-Tyr-Cys-

AB The 18-residue peptide T22 (I; X = Q) has been shown to have a strong anti-HIV activity comparable to that of AZT. Several shortened analogs of T22 were designed, synthesized and evaluated of their anti-HIV activities. The 14-residue peptide I (X = D-Lys-Pro), with one disulfide bond, showed comparable activity to that of T22, indicating that the mol. size of T22 could be reduced without loss of the activity.

IT 181128-59-6P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(prepn. and anti-HIV activity of chain-shortened peptide T22 analogs)

RN 181128-59-6 CAPLUS


CN L-Argininamide, L-arginyl-L-arginyl-L-tryptophyl-L-cysteinyl-L-tyrosyl-L-arginyl-L-lysyl-N6-glycyl-D-lysyl-L-prolyl-L-tyrosyl-L-arginyl-L-lysyl-L-cysteinyl-, cyclic (4.fwdarw.13)-disulfide (9CI) (CA INDEX NAME)



Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





L36 ANSWER 14 OF 21 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1996:50412 CAPLUS

DOCUMENT NUMBER: 124:106667

TITLE: Peptide drugs for treatment of angina pectoris

INVENTOR(S): Tomita, Mamoru; Kawashima, Takuji; Shimamura, Seiichi;

Takase, Mitsunori; Origasa, Shuzo

PATENT ASSIGNEE(S): Morinaga Milk Industry Co Ltd, Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07278011	A2	19951024	JP 1994-85243	19940401
PRIORITY APPLN. INFO.:			JP 1994-85243	19940401
AB Peptides and their salts and/or >2 single peptide mixt. are claimed as active principles for treatment of angina pectoris. The peptides are heat resistant, water sol., and stable in aq. solns. and have minimal toxicity and side effects. The peptides can be formulated into any dosage forms without adding preservatives because the peptides them self have antibacterial activities. Animal studies indicated that the antianginal effects of these peptides are comparable to that of nitroglycerin.				
IT 146285-68-9 146285-69-0 146285-73-6 146285-74-7				
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
(peptide drugs for treatment of angina pectoris)				
RN	146285-68-9	CAPLUS		
CN	L-Tryptophan, L-arginyl-L-arginyl-L-tryptophyl-L-glutaminy- (9CI) (CA INDEX NAME)			


Absolute stereochemistry.



RN 146285-69-0 CAPLUS

CN L-Glutamine, L-arginyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 146285-73-6 CAPLUS

CN L-Asparagine, L-leucyl-L-arginyl-L-tryptophyl-L-glutaminyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 146285-74-7 CAPLUS

CN L-Glutamine, L-leucyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L36 ANSWER 15 OF 21 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1996:38665 CAPLUS

DOCUMENT NUMBER: 124:97742

TITLE: Lactoferrin-related peptides as heparin-neutralizing agents and pharmaceutical compositions containing the peptides

INVENTOR(S): Kawashima, Takuji; Tomita, Mamoru; Shimamura, Seiichi; Takase, Mitsunori; Origasa, Shuzo

PATENT ASSIGNEE(S): Morinaga Milk Industry Co Ltd, Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 11 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07291874	A2	19951107	JP 1994-85143	19940422

PRIORITY APPLN. INFO.: JP 1994-85143 19940422

AB Lactoferrin-related peptides (sequences given) or their pharmaceutically acceptable salts are heparin-neutralizing agents and pharmaceutical compns. contg. the peptides are useful for e.g. inhibiting excessive hemorrhage due to use of antithrombotic heparin in surgery. The peptides

also showed antimicrobial activities. Thus, peptide 1 and NaCl 9 mg were dissolved in 1 mL injection water and the soln. was adjusted to pH 7, filtered, and distributed into an ampule.


IT 146285-68-9 146285-69-0 146285-73-6  
146285-74-7

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(lactoferrin-related peptides as heparin-neutralizing agents and pharmaceutical compns. contg. the peptides)

RN 146285-68-9 CAPLUS

CN L-Tryptophan, L-arginyl-L-arginyl-L-tryptophyl-L-glutamyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 146285-69-0 CAPLUS

CN L-Glutamine, L-arginyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 146285-73-6 CAPLUS

CN L-Asparagine, L-leucyl-L-arginyl-L-tryptophyl-L-glutamyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 146285-74-7 CAPLUS

CN L-Glutamine, L-leucyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L36 ANSWER 16 OF 21 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1994:183040 CAPLUS

DOCUMENT NUMBER: 120:183040

TITLE: Peptide and antisense oligonucleotide inhibitors of protein kinase C

INVENTOR(S): Diaz-Meco, Conde Marie Teresa; Moscat, Guillen Jorge

PATENT ASSIGNEE(S): Glaxo S.A., Spain

SOURCE: PCT Int. Appl., 57 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9320101	A1	19931014	WO 1993-EP816	19930402
W: JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 592634	A1	19940420	EP 1993-908891	19930402
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 06508154	T2	19940914	JP 1993-517110	19930402
PRIORITY APPLN. INFO.:			EP 1992-500034	19920406
			WO 1993-EP816	19930402
OTHER SOURCE(S):		MARPAT 120:183040		

Searched by Barb O'Bryen, STIC 308-4291

AB Peptides X-Ala-Arg-Arg-J (X = H, .gtoreq.1 amino acid; J = OH, .gtoreq.1 amino acid), contg. 3-15 amino acid residues, and antisense oligonucleotides corresponding to the DNA coding for .zeta.-protein kinase C (I), esp. GGTCCTGCTGGGCAT, inhibit I. These peptides and oligonucleotides are, thus, of use in medicine for the treatment of conditions whose underlying etiol. is assocd. with I activity, e.g. tumors, hyperproliferative disorders, and viral infections. Peptide Arg-Arg-Gly-Ala-Arg-Arg-Trp-Arg-Lys inhibited DNA synthesis in proliferating NIH-3T3 fibroblasts.


IT 151898-36-1 151898-37-2

RL: BIOL (Biological study)  
(protein kinase C zeta inhibitor)

RN 151898-36-1 CAPLUS

CN L-Tryptophan, N-[N2-(N2-L-alanyl-L-arginyl)-L-arginyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 151898-37-2 CAPLUS

CN L-Arginine, N2-[N-[N2-(N2-L-alanyl-L-arginyl)-L-arginyl]-L-tryptophyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L36 ANSWER 17 OF 21 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1993:109438 CAPLUS

DOCUMENT NUMBER: 118:109438


TITLE: Antimicrobial peptides



INVENTOR(S): Tomita, Mamoru; Kawase, Kozo; Takase, Mitsunori;  
Bellamy, Wayne Robert; Yamauchi, Koji; Wakabayashi,  
Hiroyuki; Tokita, Yukiko  
PATENT ASSIGNEE(S): Morinaga Milk Industry Co., Ltd., Japan  
SOURCE: Eur. Pat. Appl., 21 pp.  
CODEN: EPXXDW  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 510912	A1	19921028	EP 1992-303542	19920421
EP 510912	B1	19980107		
R: BE, CH, DE, DK, FR, GB, IT, LI, NL, SE				
CA 2066997	AA	19921025	CA 1992-2066997	19920424
AU 9215146	A1	19921029	AU 1992-15146	19920424
AU 664697	B2	19951130		
JP 05148295	A2	19930615	JP 1992-107067	19920424
JP 3323226	B2	20020909		
US 5424396	A	19950613	US 1993-165545	19931213
PRIORITY APPLN. INFO.:			JP 1991-94494	A 19910424
			US 1992-871981	B1 19920422
AB	Antimicrobial peptides contg. .gtoreq. 3-6 amino acid residues are prepd. and used at .gtoreq. 2.mu.M concn. in pharmaceuticals, cosmetics and foods. Arg-Arg-Trp-Gln (I) (prepn. is given) was added to pasteurized milk at 30 .mu.M and kept at 30.degree.. The milk solidified in 10 days as compared to 2 days for control. A toothpaste contained. sorbitol 47.0, glycerin 15.0, Na CM-cellulose 2.0, sorbitan fatty acid ester 1.0, Na saccharin 1.0, and I 0.002%.			
IT	<b>146285-68-9P 146285-69-0P 146285-73-6P 146285-74-7P</b> RL: BUU (Biological use, unclassified); FFD (Food or feed use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of, <b>antimicrobial</b> , for cosmetics and pharmaceaticals and food)			
RN	146285-68-9 CAPLUS			
CN	L-Tryptophan, L-arginyl-L-arginyl-L-tryptophyl-L-glutaminyL- (9CI) (CA INDEX NAME)			


Absolute stereochemistry.



RN 146285-69-0 CAPLUS

CN L-Glutamine, L-arginyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 146285-73-6 CAPLUS

CN L-Asparagine, L-leucyl-L-arginyl-L-tryptophyl-L-glutaminyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 146285-74-7 CAPLUS

CN L-Glutamine, L-leucyl-L-arginyl-L-tryptophyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L36 ANSWER 18 OF 21 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1993:81448 CAPLUS

DOCUMENT NUMBER: 118:81448

TITLE: Preparation of antimicrobial peptide compositions

INVENTOR(S): Tomita, Mamoru; Kawase, Kozo; Takase, Mitsunori; Bellamy, Wayne Robert; Yamauchi, Koji; Wakabayashi, Hiroyuki; Tokita, Yukiko

PATENT ASSIGNEE(S): Morinaga Milk Industry Co., Ltd., Japan

SOURCE: Eur. Pat. Appl., 19 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 503939.	A1	19920916	EP 1992-302125	19920312
EP 503939	B1	19970618		
R: BE, CH, DE, DK, FR, GB, IT, LI, NL, SE				
CA 2063063	AA	19920914	CA 1992-2063063	19920313
AU 9212905	A1	19920917	AU 1992-12905	19920313
AU 659440	B2	19950518		
JP 05078392	A2	19930330	JP 1992-55741	19920313

JP 2771068	B2	19980702		
US 5428016	A	19950627	US 1992-851941	19920313
JP 05148296	A2	19930615	JP 1992-104932	19920423
JP 3173857	B2	20010604		
JP 05148297	A2	19930615	JP 1992-104933	19920423
JP 3173858	B2	20010604		

## PRIORITY APPLN. INFO.:

JP 1991-48196	A	19910313
JP 1991-94492	A	19910424
JP 1991-94493	A	19910424

OTHER SOURCE(S): MARPAT 118:81448

AB Antimicrobial peptides H-A-X-A-R (I; A = Arg, Lys; X = 3-9 arbitrary amino acid residues other than cysteine; R = OH, NH<sub>2</sub>), fragment analogs of lactoferrin, were prepd. by solid-phase methods as antimicrobial agents. I are active at a concn. of at least 1 .mu.m, and compns. contg. I and methods for processing products with I are given.

IT 145617-76-1P 145617-80-7P 145617-91-0P


RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of, by solid-phase method, as **antimicrobial** agent)

RN 145617-76-1 CAPLUS


CN L-Arginine, L-arginyl-L-tryptophyl-L-glutamyl-L-tryptophyl- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 145617-80-7 CAPLUS  
 CN L-Lysine, L-arginyl-L-tryptophyl-L-glutaminyl-L-.alpha.-glutamyl- (9CI)  
 (CA INDEX NAME)


Absolute stereochemistry.




RN 145617-91-0 CAPLUS  
 CN L-Argininamide, L-arginyl-L-tryptophyl-L-glutaminyl-L-tryptophyl- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



L36 ANSWER 19 OF 21 CAPLUS COPYRIGHT 2003 ACS  
ACCESSION NUMBER: 1992:551411 CAPLUS  
DOCUMENT NUMBER: 117:151411  
TITLE: Synthesis of equimolar multiple oligomer mixtures,  
especially of oligopeptide mixtures  
INVENTOR(S): Houghten, Richard A.; Cuervo, Julio Hernan; Pinilla,  
Clemencia; Appel, Jon R., Jr.; Blondelle, Silvie  
PATENT ASSIGNEE(S): Interex Pharmaceuticals Ltd. Partnership, USA  
SOURCE: PCT Int. Appl., 197 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 4  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9209300	A1	19920611	WO 1991-US8694	19911120
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
CA 2090860	AA	19920522	CA 1991-2090860	19911120
AU 9191418	A1	19920625	AU 1991-91418	19911120
AU 668347	B2	19960502		
EP 558671	A1	19930908	EP 1992-902209	19911120
EP 558671	B1	19990127		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AT 176239	E	19990215	AT 1992-902209	19911120
ES 2129442	T3	19990616	ES 1992-902209	19911120
US 5504190	A	19960402	US 1994-253854	19940603
PRIORITY APPLN. INFO.:			US 1990-617023	A 19901121
			US 1991-701658	A 19910516
			US 1991-797551	19911119
			WO 1991-US8694	A 19911120
AB	A method is described for prepg. mixts. of oligopeptides by the solid-phase method. These mixts. were then tested by a monoclonal antibody binding assay to identify the most active sequences, as well as for bactericidal, fungicidal, and virucidal activity. Thus, Ac-Arg-Arg-Trp-Trp-Cys-Arg-NH <sub>2</sub> had a monoclonal antibody-binding Ed <sub>50</sub> of 3.4 .mu.g/mL and a min. inhibitory concn. against Staphylococcus aureus of 3.2-6.5 .mu.g/mL.			
IT	<b>143460-19-9P</b> RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)			
RN	143460-19-9 CAPLUS			
CN	L-Cysteine, L-arginyl-L-arginyl-L-tryptophyl-L-tryptophyl- (9CI) (CA INDEX NAME)			

Absolute stereochemistry.



L36 ANSWER 20 OF 21 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1992:15339 CAPLUS

DOCUMENT NUMBER: 116:15339

TITLE: Minimum analog peptide sets (MAPS) for quantitative structure-activity relationships

AUTHOR(S): Hellberg, Sven; Eriksson, Lennart; Jonsson, Joergen; Lindgren, Fredrik; Sjoestroem, Michael; Skagerberg, Bert; Wold, Svante; Andrews, Peter

CORPORATE SOURCE: Dep. Chem., Univ. Umea, Umea, S-90187, Swed.

SOURCE: International Journal of Peptide & Protein Research (1991), 37(5), 414-24

CODEN: IJPPC3; ISSN: 0367-8377

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The previously published peptide sets were compared with smaller sets of peptides selected according to statistical designs. Min. analog peptide sets (MAPS) constructed by factorial or fractional factorial designs in physicochem. properties contained substantial structure-activity information. Although five to six times smaller than the originally published peptide sets, the MAPS resulted in QSAR models able to predict biol. activity. The QSARs derived from a MAPS of 9 dipeptides and from 58 dipeptides inhibiting angiotensin-converting enzyme were of equal strength. For a set of bitter tasting dipeptides, an incomplete MAPS of 10 dipeptides gave just as good a model as the model based on a set of 48 dipeptides. Other non-designed sets of peptides gave QSARs with poor predictive power. MAPS centered on a lead peptide can be constructed to explore specifically the physicochem. and biol. properties in the vicinity of the lead. Small information-rich peptide sets MAPS can be constructed on the basis of statistical designs with principal properties of amino acids as design variables.

IT 135700-69-5



RL: PRP (Properties)

(virucidal effects of, min. analog set technique for structure design in relation to)

RN 135700-69-5 CAPLUS

CN L-Threonine, N-[N-[N2-(N-L-threonyl-L-seryl)-L-arginyl]-L-tryptophyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L36 ANSWER 21 OF 21 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1989:232056 CAPLUS

DOCUMENT NUMBER: 110:232056

TITLE: Interaction of basic extension peptide fragments of  
adrenodoxin precursor with phospholipid vesicles  
AUTHOR(S): Aoyagi, Haruhiko; Lee, Sannamu; Nakamura, Hiroshi;  
Park, Nam Gyu; Kato, Tetsuo  
CORPORATE SOURCE: Fac. Sci., Kyushu Univ., Fukuoka, Japan  
SOURCE: International Journal of Peptide & Protein Research  
(1988), 32(5), 406-14  
CODEN: IJPPC3; ISSN: 0367-8377

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 110:232056

AB Two extension peptide fragments, PA1-14 and PA17-32, which correspond to the residues 1-14 and 17-32, resp., of adrenodoxin precursor, were synthesized by the soln. method to find a sequence necessary for the import of the precursor into mitochondria. Biol. assay showed that PA1-14 inhibited the import of two mitochondrial enzyme precursors, but PA17-32 showed no inhibition, indicating that the N-terminal sequence has important information for import. CD spectra of the peptides demonstrated that PA1-14 formed an  $\alpha$ -helical structure in Tris-HCl buffer (pH 7.4) contg. acidic phospholipid liposomes. Furthermore, PA1-14 induced the moderate leakage of carboxyfluorescein from phospholipid vesicles. The relationship between the structure and function of the peptides is discussed.

IT **120776-15-0P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. and deblocking of, with hydrogen chloride)

RN 120776-15-0 CAPLUS

CN L-Leucine, N-[N2-[N-[N2-[(1,1-dimethylethoxy)carbonyl]-N5-[imino[[ (4-methylphenyl)sulfonyl]amino]methyl]-L-ornithyl]-L-tryptophyl]-N5-[imino[[ (4-methylphenyl)sulfonyl]amino]methyl]-L-ornithyl]-, 2-oxo-2-phenylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





IT 120776-16-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(prepn. and peptide coupling of, with alanylglycine active ester)

RN 120776-16-1 CAPLUS

CN L-Leucine, N-[N5-[imino[[ (4-methylphenyl)sulfonyl]amino]methyl]-N2-[N-[N5-[imino[[ (4-methylphenyl)sulfonyl]amino]methyl]-L-ornithyl]-L-tryptophyl]-L-ornithyl]-, 2-oxo-2-phenylethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

HCl

